Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.39 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.38 |
| ▸ | SELE | P16581 | 1/20 | 0.38 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.38 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22000038 | 0.84 | SLC6A2 (0.46) | MAPTTDP1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4740349 | 0.72 | ESR1 (0.41) | L3MBTL1MAPTMEN1KMT2ATDP1 | |
| SCHEMBL5567324 | 0.72 | TSHR (0.37) | L3MBTL1SMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL5420160 | 0.70 | SLC6A4 (0.43) | NPC1RAB9ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17295781 | 0.69 | FBP1 (0.43) | SMN1; SMN2NPC1MAPTRAB9AMEN1 | |
| SCHEMBL24252491 | 0.69 | SLC6A2 (0.45) | L3MBTL1SMN1; SMN2NPC1MAPTRAB9A | |
| SCHEMBL4468516 | 0.69 | SCN9A (0.41) | SMN1; SMN2MAPTRAB9AMEN1KMT2A | |
| SCHEMBL3577014 | 0.69 | ALDH1A1 (0.46) | ALDH1A1TSHRFBP1 | |
| SCHEMBL8054019 | 0.69 | TTR (0.66) | L3MBTL1MAPTTDP1SLC6A2SLC6A4 | |
| SCHEMBL22619480 | 0.68 | ACLY (0.40) | SMN1; SMN2NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2024-04-04 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| CN-116947903-A | Inhibitors of complement factors and uses thereof | 安尼艾克松股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-116261564-A | Inhibitors of complement factors and uses thereof | 安尼艾克松股份有限公司 | 2023-06-13 | — | — | CN | disclosed |
| EP-4185592-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | Annexon, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | L3MBTL1 4785/4885SMN1; SMN2 782/4885NPC1 460/4885 |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | L3MBTL1 4785/4885SMN1; SMN2 782/4885NPC1 460/4885 |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | L3MBTL1 4785/4885SMN1; SMN2 782/4885NPC1 460/4885 |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | SSB, UACA, CFH | L3MBTL1 2967/4885SMN1; SMN2 237/4885NPC1 4343/4885 |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFH, CFB, C5 | L3MBTL1 3721/4885SMN1; SMN2 1451/4885NPC1 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.